HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Powers, M. V Articles by Workman, P. Search for Related Content PubMed PubMed Citation Articles by Powers, M. V Articles by Workman, P.

Signal Transduction and Molecular Pharmacology Team, Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK

(Requests for offprints should be addressed to P Workman; Email: paul.workman{at}icr.ac.uk)

This paper was presented at the 2nd Tenovus/AstraZeneca Workshop, Cardiff (2006). AstraZeneca supported the meeting and the Welsh School of Pharmacy, Cardiff University has supported the publication of these proceedings.

The last decade has seen the molecular chaperone heat shock protein 90 (HSP90) emerge as an exciting target for cancer therapy. This is because HSP90 is involved in maintaining the conformation, stability, activity and cellular localisation of several key oncogenic client proteins. These include, amongst others, ERBB2, C-RAF, CDK4, AKT/PKB, steroid hormone receptors, mutant p53, HIF-1 , survivin and telomerase hTERT. Therefore, modulation of this single drug target offers the prospect of simultaneously inhibiting all the multiple signalling pathways and biological processes that have been implicated in the development of the malignant phenotype. The chaperone function of HSP90 requires the formation of a multichaperone complex, which is dependent on the hydrolysis of ATP and ADP/ATP exchange. Most current inhibitors of HSP90 act as nucleotide mimetics, which block the intrinsic ATPase activity of this molecular chaperone. The first-in-class inhibitor to enter and complete phase I clinical trials was the geldanamycin analogue, 17-allylamino-17-demethoxygeldanamycin. The results of these trials have demonstrated that HSP90 is a valid drug target. Evidence of clinical activity has been seen in patients with melanoma, breast and prostate cancer. This article provides a personal perspective of the present efforts to increase our understanding of the molecular and cellular consequences of HSP90 inhibition, with examples from work in our own laboratory. We also review the discovery and development of novel small-molecule inhibitors and discuss alternative approaches to inhibit HSP90 activity, both of which offer exciting prospects for the future.

This article has been cited by other articles:

				W. Guo, P. Reigan, D. Siegel, and D. Ross Enzymatic Reduction and Glutathione Conjugation of Benzoquinone Ansamycin Heat Shock Protein 90 Inhibitors: Relevance for Toxicity and Mechanism of Action Drug Metab. Dispos., October 1, 2008; 36(10): 2050 - 2057. [Abstract] [Full Text] [PDF]

				A. K. McCollum, C. J. TenEyck, B. Stensgard, B. W. Morlan, K. V. Ballman, R. B. Jenkins, D. O. Toft, and C. Erlichman P-Glycoprotein-Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response Cancer Res., September 15, 2008; 68(18): 7419 - 7427. [Abstract] [Full Text] [PDF]

				R. R. Almon, E. Yang, W. Lai, I. P. Androulakis, D. C. DuBois, and W. J. Jusko Circadian Variations in Rat Liver Gene Expression: Relationships to Drug Actions J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 700 - 716. [Abstract] [Full Text] [PDF]

				M. A. Alaamery and C. S. Hoffman Schizosaccharomyces pombe Hsp90/Git10 Is Required for Glucose/cAMP Signaling Genetics, April 1, 2008; 178(4): 1927 - 1936. [Abstract] [Full Text] [PDF]

				A. Chatterjee, C. Snead, G. Yetik-Anacak, G. Antonova, J. Zeng, and J. D. Catravas Heat shock protein 90 inhibitors attenuate LPS-induced endothelial hyperpermeability Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L755 - L763. [Abstract] [Full Text] [PDF]

				U. Banerji, A. Affolter, I. Judson, R. Marais, and P. Workman BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors Mol. Cancer Ther., April 1, 2008; 7(4): 737 - 739. [Abstract] [Full Text] [PDF]

				M. M. McCarthy, E. Pick, Y. Kluger, B. Gould-Rothberg, R. Lazova, R. L. Camp, D. L. Rimm, and H. M. Kluger HSP90 as a marker of progression in melanoma Ann. Onc., March 1, 2008; 19(3): 590 - 594. [Abstract] [Full Text] [PDF]

				Consensus Statement Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S1 - S2. [Full Text] [PDF]